Fidia's Hyalgan osteoarthritis injection U.S. launch to be backed by Sanofi, OrthoLogic direct reps.
This article was originally published in The Gray Sheet
Executive Summary
FIDIA'S HYALGAN TO BE BACKED BY 415-REP U.S. SALES FORCE in a market introduction of the hyaluronic acid-based knee joint injection product planned for July. Under an exclusive U.S. licensing deal announced June 25, Sanofi Pharmaceuticals will offer the product through 250 reps to rheumatologists, family practice physicians and others who treat osteoarthritis except for orthopedic surgeons. A separate co-promotion agreement between Sanofi and OrthoLogic will provide an additional 165 reps targeting orthopedic surgeons.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.